INMB | The TYP

Blog Posts

Mar 8, 20226 min read

NFL AS A HIGHLY RELEVANT BIOMARKER IN AD AND OTHER NEUROLOGICAL DISEASES

What is neurofilament-light chain (NfL)? Neurofilaments, the larger group to which NfL belongs, are structural components of neuronal...

Mar 6, 20226 min read

THE CURIOUS CASE OF CORTEXYME AND HOW I RELATE IT TO INMUNE BIO

What most investors seem to forget is diving into scientific literature The trials and tribulations of the stock market seem, to me, in...

Jan 9, 202214 min read

THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO: PARTNERSHIP/BUYOUT AND VALUATION CONSIDERATIONS

My views on possible partnership/buyout and valuation of INMB will be set out below. The highlights are the following. - I consider a...

Dec 29, 202110 min read

THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART IV: A DEEPER DIVE INTO INKMUNE

The immuno-oncology platform INKmune of INmune Bio may be a better, easier to produce and cheaper product candidate than others.

Dec 21, 202114 min read

THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART III: AN INTRODUCTION TO INKMUNE

INTRODUCTION As an immunotherapy drug candidate, INKmune seems by far the most commercially sustainable, undervalued that I am aware of....

Dec 17, 202111 min read

THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART II

Drug XPro of INmune Bio has limitless potential in neurodegenerative diseases such as Alzheimers, ALS, MS, Huntington's, Parkinson's, ...